MedPath
EMA Product

Fortacin

Product approved by European Medicines Agency (EU)

Basic Information

Fortacin

Regulatory Information

EMEA/H/C/002693

Authorised

November 15, 2013

September 19, 2013

13

February 3, 2025

Company Information

Ireland

Raheens East Ringaskiddy, Co. Cork,

Recordati Ireland Ltd.

Active Substances Detail

lidocaineprilocaine

Detailed Information

Therapeutic Indication

### Therapeutic indication Treatment of primary premature ejaculation in adult men.

Overview Summary

Fortacin is used to treat men with primary (lifelong) premature ejaculation (when ejaculation regularly occurs before, or too early during, penetration). Fortacin contains the active substances lidocaine and prilocaine.

© Copyright 2025. All Rights Reserved by MedPath